Safety and Efficacy of Favipiravir for the management of COVID-19 Patients: A Randomized Control Trial

Rahman et al., Clinical Infection in Practice, doi:10.1016/j.clinpr.2022.100145, NCT04402203 (history)

Rahman et al., Safety and Efficacy of Favipiravir for the management of COVID-19 Patients: A Randomized Control Trial, Clinical Infection in Practice, doi:10.1016/j.clinpr.2022.100145, NCT04402203

May 2022 Source PDF

Twitter
Facebook

All Studies Meta

RCT hospitalized patients in Bangladesh, showing faster recovery and viral clearance with favipiravir treatment.

Important missing comments or errors? Let us know.

risk of no chest x-ray improvement, 89.5% lower, RR 0.11, p = 0.005, treatment 1 of 19 (5.3%), control 8 of 16 (50.0%), NNT 2.2, day 10.

risk of no chest x-ray improvement, 64.9% lower, RR 0.35, p = 0.007, treatment 5 of 19 (26.3%), control 12 of 16 (75.0%), NNT 2.1, day 7.

risk of no chest x-ray improvement, 47.4% lower, RR 0.53, p = 0.001, treatment 10 of 19 (52.6%), control 16 of 16 (100.0%), NNT 2.1, day 4.

risk of no viral clearance, 91.7% lower, RR 0.08, p < 0.001, treatment 1 of 25 (4.0%), control 12 of 25 (48.0%), NNT 2.3, day 10.

risk of no viral clearance, 62.5% lower, RR 0.38, p = 0.010, treatment 6 of 25 (24.0%), control 16 of 25 (64.0%), NNT 2.5, day 7.

risk of no viral clearance, 48.0% lower, RR 0.52, p < 0.001, treatment 13 of 25 (52.0%), control 25 of 25 (100.0%), NNT 2.1, day 4.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Rahman et al., 13 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Bangladesh, peer-reviewed, mean age 37.8, 10 authors, study period May 2020 - July 2020, trial NCT04402203 (history).

Contact: smarahman@du.ac.bd.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Favipiravir All

Safety and efficacy of favipiravir for the management of COVID-19 patients: A preliminary randomized control trial

S M Abdur Rahman, Ahmedul Kabir, Md Abm B M Abdullah, Md Billal Alam, Khan Abul Kalam Azad, Md Titu Miah, Syed Ghulam Mogni Mowla, Sudip Ranjan Deb, Mohammad Robed Amin, Muhammad Asaduzzaman

Clinical Infection in Practice, doi:10.1016/j.clinpr.2022.100145

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Table-5: Assessment of Adverse effects of patients of both groups 4%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Jaundice 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Skin rash 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Liver damage 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2(8%) 0 (0%) 1 (4%) Anemia 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Vertigo 2 (8%) 2 (8%) 2 (8%) 2 (8%) 0 (0%) 2 (8%) 0 (0%) 1 (4%) Anosmia 1 (4%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Conflict of Interest: The authors declared that there was no conflict of interest regarding the clinical trial. Funding: Beacon Pharmaceuticals Limited, Dhaka, Bangladesh. References Author Contributions:

References

Alam, Kamal, Sarkar, Zhou, Rahman et al., Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021, Front Pharmacol, doi:10.3389/fphar.2021.659577

Cai, Experimental treatment with favipiravir for COVID-19 : An open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007

Callender, The impact of Pre-existing comorbidities and Therapeutic Interventions on COVID-19, Front. Immunol, doi:10.3389/fimmu.2020.01991

Chen, Favipiravir versus arbidol for COVID-19: A randomized clinical trial, doi:10.1101/2020.03.17.20037432

Cucinotta, Vanelli, WHO declares COVID-19 a pandemic, Acta Biomed

Delang, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, Antiviral Res

Du, Chen, Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clinical Pharmacology and Therapeutics

Filho, Covid-19 and the UN Sustainable Development Goals: Threat to Solidarity or an Opportunity?, Sustainability, doi:10.3390/su12135343

Furuta, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci

Furuta, Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res

Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Scientific reports

Hossain, Hridoy, Rahman, Ahmad, Major depressive and Generalized anxiety disorders among university students during the second wave of COVID-19 outbreak in Bnagladesh. Asia Pac, J. Pubic Health

Hossain, Rahman, Repurposing therapeutic agents againsts SARS-CoV-2 infection: most promising and neoteric progress, Expert Rev Antiinfective Therapy, doi:10.1080/14787210.2021.1864327

Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet

Li, Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat Rev Drug Discov

Lu, Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle, J Med Virol, doi:10.1002/jmv.25678

Nicola, The Socio-economic implications of the coronavirus pandemic (COVID-19): A review, Int. J. Surg

Nigata, Favipiravir: a new medication for the ebola virus disease pandemic, Disaster Medicine and Public Health preparedness

Pilkington, A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic?, J. Virus Erad

Roser, Coronavirus Disease (COVID-19)-Statistics and Research

Sleeman, In vitro antiviral activity of favipiravir (T-705 ) against drug-resistant influenza and 2009 a (H1N1) viruses, Antimicrob Agents Chemother

Wang, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA

Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019nCoV) in vitro, Cell Res

Weiss, Murdoch, Clinical course and mortality risk of severe COVID-19, Lancet

Zhou, Clinical course and risk factors mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study, Lancet

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit